Literature DB >> 32144535

Risk factors for survival and distant metastasis in 125 patients with head and neck adenoid cystic carcinoma undergoing primary surgery.

In Seong Jeong1, Jong-Lyel Roh2, Kyung-Ja Cho3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

PURPOSE: Adenoid cystic carcinoma (AdCC) is generally slow growing but has highly metastatic potential to distant organs. Several factors and biomarkers are associated with metastasis and treatment outcomes, although further definition is needed. Therefore, this study aimed to evaluate the risk factors for survival and distant metastasis in patients with head and neck AdCC.
METHODS: This study included 125 patients with previously untreated AdCC who underwent primary surgery with or without radiotherapy in our tertiary referral centre. Univariate and multivariate Cox proportional hazard regression analyses were used to identify risk factors associated with overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), and distant metastasis-free survival (DMFS). Factors associated with OS in patients with distant metastasis were separately analysed.
RESULTS: During a median follow-up of 9.8 years (range 3.0-22.6 years), 58 patients (46.4%) had distant metastasis and 29 (23.2%) died of disease. Multivariate analyses showed that lymphovascular invasion, lymph node metastasis, and distant metastasis were independent factors of OS and CSS outcomes (all P < 0.05). The T classification and extranodal extension were independent factors of DFS and DMFS outcomes (P < 0.05). After patients presented with distant metastasis, the median survival was 5.8 years. Multivariate analyses showed that extranodal extension and regional recurrence were independent factors of survival after occurrence of distant metastasis (P < 0.05).
CONCLUSION: Several clinicopathological factors can predict distant metastasis and survival of patients with AdCC treated with primary surgery. This may promote post-treatment surveillance in patients with AdCC.

Entities:  

Keywords:  Adenoid cystic carcinoma; Distant metastasis; Head and neck; Risk factors; Survival

Mesh:

Year:  2020        PMID: 32144535     DOI: 10.1007/s00432-020-03170-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  World Health Organization classification of tumours: pathology and genetics of head and neck tumours.

Authors:  Lester Thompson
Journal:  Ear Nose Throat J       Date:  2006-02       Impact factor: 1.697

2.  Clinicopathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands: A clinical analysis of 130 cases.

Authors:  Shizhi He; Pingdong Li; Qi Zhong; Lizhen Hou; Zhenkun Yu; Zhigang Huang; Xuejun Chen; Jugao Fang; Xiaohong Chen
Journal:  Am J Otolaryngol       Date:  2016-11-23       Impact factor: 1.808

3.  Multicollinearity in Regression Analyses Conducted in Epidemiologic Studies.

Authors:  Kristina P Vatcheva; MinJae Lee; Joseph B McCormick; Mohammad H Rahbar
Journal:  Epidemiology (Sunnyvale)       Date:  2016-03-07

4.  Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy.

Authors:  Shane Lloyd; James B Yu; Lynn D Wilson; Roy H Decker
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

5.  Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study.

Authors:  Shinji Takebayashi; Shogo Shinohara; Hisanobu Tamaki; Ichiro Tateya; Morimasa Kitamura; Masanobu Mizuta; Shinzo Tanaka; Tsuyoshi Kojima; Ryo Asato; Toshiki Maetani; Koji Ushiro; Yoshiharu Kitani; Kazuyuki Ichimaru; Keigo Honda; Koichiro Yamada; Koichi Omori
Journal:  Acta Otolaryngol       Date:  2017-09-12       Impact factor: 1.494

Review 6.  Adenoid cystic carcinoma of the head and neck--An update.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Patrick J Bradley; Vincent Vander Poorten; Asterios Triantafyllou; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Missak Haigentz; Robert P Takes; Vanni Mondin; Afshin Teymoortash; Lester D R Thompson; Alfio Ferlito
Journal:  Oral Oncol       Date:  2015-05-02       Impact factor: 5.337

7.  Extranodal extension and thickness of metastatic lymph node as a significant prognostic marker of recurrence and survival in head and neck squamous cell carcinoma.

Authors:  Minsu Kwon; Jong-Lyel Roh; Jungbok Lee; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Craniomaxillofac Surg       Date:  2015-04-30       Impact factor: 2.078

8.  Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases.

Authors:  Tao Yu; Qing-Hong Gao; Xiao-Yi Wang; Yu-Ming Wen; Long-Jiang Li
Journal:  Oncology       Date:  2007-11-12       Impact factor: 2.935

Review 9.  Adenoid cystic carcinoma of the head and neck--a 20 years experience.

Authors:  H Kokemueller; A Eckardt; P Brachvogel; J-E Hausamen
Journal:  Int J Oral Maxillofac Surg       Date:  2004-01       Impact factor: 2.789

Review 10.  Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience.

Authors:  Nerina Denaro; Marco Carlo Merlano; Elvio Grazioso Russi
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-06-25       Impact factor: 3.372

View more
  3 in total

1.  Low-dose radiotherapy combined with immunotherapy for suboral adenoid cystic carcinoma with bilateral lung metastasis: A case report and literature review.

Authors:  Danyang Li; Xuezhou Pang; Xinxin Zhu; Qiyue Shanzhou; Guo Wen; Daiyuan Ma
Journal:  Oncol Lett       Date:  2022-06-24       Impact factor: 3.111

2.  Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study.

Authors:  Ning Su; Yu Fang; Jinni Wang; Xiaopeng Tian; Shuyun Ma; Jun Cai; Yuchen Zhang; Yi Xia; Panpan Liu; Qingqing Cai
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

3.  Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.

Authors:  Shengnan Zheng; Huiying Li; Yongjuan Lin; Yu Xie; Zhenyu Yin; Weihong Ge; Tingting Yu
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.